Temedica has closed an additional 25 Euro million Series B financing to expand its Real-World Evidence ecosystem, bringing its total Series B financing to 42 million euros.
Temedica from Munich wants to make a significant contribution to the development of individual, patient-oriented care. To this end, the health insights company combines its real-world insights platform Permea and patient companion apps.
Billions of data points for more and better health
From more than 40 billion data points on over 50,000 diagnoses, Temedica derives health-relevant insights into disease progression, the effectiveness of therapies, patient journeys, and medication adherence. In the process, data from a wide variety of sources are combined. The insights gained from the connected data are intended to provide tangible added value to all stakeholders in the healthcare system.
Among other things, the information and insights collected by Temedica are fed back directly to patients via Temedica's patient companion apps. In this way, patients will gain an individualized understanding of their disease as well as the connections with their lifestyle and be able to actively influence their condition.
Gloria Seibert, Founder & Chief Executive Officer of Temedica, says:
Temedica's vision is to make a pioneering contribution to the development of personalized medicine by linking health-relevant data to new, evidence-based insights. We are convinced that big data sets and completely new types of data play a key role in this, such as patient-generated data from large populations outside of classic clinical trials. These enable a completely new knowledge and understanding of diseases and their actual courses. I am very pleased that our investors share this vision and accompany and support us as we continue to expand the Temedica ecosystem.”
The expansion of the financing round is led by existing investors MIG Capital as well as a Munich-based family office, underlining their sustained support for Temedica's relevant and ambitious goals of personalized medicine and data-based healthcare decisions.
Boris Bernstein, partner of MIG Capital, emphasizes: “Temedica is operating in a massively growing and highly attractive market. The newly developed real-world insights platform Permea provides pharmaceutical companies with a deep understanding of patients and their care in the real world, outside of clinical trials. Access to this unique 360° understanding of care realities has the potential to revolutionize our healthcare system as we know it. The team at Temedica is highly motivated and goal-oriented, and we are excited to work with them and continue our journey together.”